FRONTEO H1 Operating Loss Widens to ¥244 Million as Risk-Management Sales Drop 24.2%; AI Drug Discovery Grows 38.3%

FRONTEO's net sales slipped 2.5% to ¥3,292 million in H1 FY3/2027 and its operating loss widened to ¥244 million from ¥7 million, as sales in the risk-management segment fell 24.2% on contract cancellations. AI drug-discovery sales rose 38.3%, and the company still expects a full-year operating profit of ¥300 million.

FRONTEO H1 FY3/2027 earnings summary

Drug discovery grows, compliance work shrinks

FRONTEO, Inc. (TSE: 2158), which applies its KIBIT natural-language AI to drug discovery, legal technology and compliance, reported consolidated results for H1 FY3/2027, April 1 to September 30, 2026, on November 16, 2026 under Japanese GAAP. Life Science AI sales rose 40.3% to ¥384 million: AI drug discovery grew 38.3% to ¥257 million as co-creation projects with drug makers accumulated, including a new project with Astellas Pharma and a second one with Santen Pharmaceutical, and AI medical devices rose 44.6% to ¥127 million, helped by one-off development revenue. The segment's loss narrowed to ¥149 million despite hiring more researchers; FRONTEO opened its KIBIT AI Biology Lab in May and was supporting seven biotech ventures at the end of September.

Risk Management sales fell 24.2% to ¥1,539 million. Business-intelligence compliance work dropped 33.7% to ¥403 million after large clients, including manufacturers, cancelled; legal-tech AI fell 17.2% to ¥904 million as e-discovery declined, partly offset by more digital-forensics work for investigation committees; and economic-security work fell 40.6% to ¥139 million. The segment swung to a ¥114 million loss despite cost cuts including an exit from overseas operations. The DX segment, made up of subsidiary Arnetz, grew sales 32.7% to ¥1,429 million and segment profit 48.8% to ¥68 million.

Second-half recovery planned

The operating loss was ¥244 million, the ordinary loss ¥229 million and the net loss attributable to owners ¥186 million, or ¥4.77 per share. Total assets fell to ¥8,761 million and the equity ratio was 39.5%. FRONTEO says its plan was always weighted to the second half and kept its full-year forecast of net sales of ¥7,600 million, operating profit of ¥300 million, ordinary profit of ¥250 million and net profit of ¥150 million. It plans no dividend.

FRONTEO, Inc. — H1 FY3/2027 (April 1 – September 30, 2026), Japanese GAAP, consolidated. Balance-sheet rows compare September 30, 2026 with March 31, 2026; guidance and dividend rows are full-year FY3/2027 against FY3/2026. "—" indicates a figure not disclosed.
MetricH1 FY3/2027H1 FY3/2026Change
Net sales (¥ million)3,2923,375−2.5%
Operating profit (¥ million)−244−7loss widened
Ordinary profit (¥ million)−229−25loss widened
Net profit attrib. to owners of parent (¥ million)−186−72loss widened
EPS (¥)−4.77−1.85loss widened
Life Science AI — revenue (¥ million)384273+40.3%
Life Science AI — segment profit (¥ million)−149−184loss narrowed
Risk Management — revenue (¥ million)1,5392,031−24.2%
Risk Management — segment profit (¥ million)−114137profit to loss
DX — revenue (¥ million)1,4291,077+32.7%
DX — segment profit (¥ million)6846+48.8%
Total assets (¥ million)8,7619,202−4.8%
Net assets (¥ million)3,6453,844−5.2%
Equity ratio39.5%39.7%−0.2 pt
FY3/2027 guidance — revenue (¥ million)7,600—−0.6%
FY3/2027 guidance — operating profit (¥ million)300—−59.4%
FY3/2027 guidance — ordinary profit (¥ million)250—−63.0%
FY3/2027 guidance — net profit (¥ million)150—−72.4%
Annual dividend per share (¥)0.000.00unchanged

JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.